Head to head
Theravance Biopharma(Delisted) vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: TBPH · VRTX
TBPH
Theravance Biopharma(Delisted)
17.03+0.00%
1-year price shape — not enough history yet
Quant Rating --
vs
VRTX
Vertex Pharmaceuticals
506.64+0.20%
1-year price shape — +23% over the period
Quant Rating C · 67/100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
| TBPH | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 17.03 | 506.64 |
| Change today | +0.00% | +0.20% |
| 1-year return | -- | +23.2% |
| Market cap | $884.18M | $128.41B |
| 52-week range | 13.08 – 21.03 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | 16.38 | 29.51 |
| P/E percentile, own 5-yr range | 86th | 74th |
| P/B | 3.05 | 6.34 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 2.06 | 15.32 |
| Net profit (TTM) | $106.95M | $3.88B |
| Revenue (TTM) | $104.31M | $12.59B |
| Revenue growth (YoY) | -20.9% | +12.5% |
| Gross margin | 100.0% | 86.0% |
| Operating margin | 9.2% | 37.9% |
| Net margin | 51.6% | 35.0% |
| Free cash flow (TTM) | $53.73M | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 93.3% | 97.2% |
| Insider activity (12mo) | 17 buy / 33 sell | 25 buy / 25 sell |
| Short interest (% of float) | 3.2% | 1.9% |
| Analyst consensus | -- | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | -- | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | -- | C (67) |
| Company | ||
| Employees | 90 | 6,400 |
| Founded | -- | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.